OCT-4、CD117表达与卵巢癌临床病理特征及预后的关系  

Relationship between expressions of OCT-4, CD117 and clinicopathological features and prognosis of patients with ovarian cancer

作　　者：乔爱琪 刘青华[2] 郗彦凤[3] 郭林芝 刘冬梅[2] 李灵敏[2] Qiao Aiqi;Liu Qinghua;Xi Yanfeng;Guo Linzhi;Liu Dongmei;Li Lingmin(Graduate School,Shanxi Medical University,Taiyuan 030001,China;Pathology Teaching and Research Office,School of Basic Medical Sciences,Shanxi Medical University,Taiyuan 030001,China;Department of Pathology,Shanxi Provincial Cancer Hospital,Taiyuan 030013,China)

机构地区：[1]山西医科大学研究生院,太原030001 [2]山西医科大学基础医学院病理教研室,太原030001 [3]山西省肿瘤医院病理科,太原030013

出　　处：《肿瘤研究与临床》2018年第8期516-520,共5页Cancer Research and Clinic

摘　　要：目的分析OCT-4、CD117在卵巢癌中的表达与患者临床病理特征及预后的关系。方法收集山西省肿瘤医院2010年2月至2016年1月70例卵巢癌患者的石蜡包埋组织，采用免疫组织化学方法检测OCT-4、CD117的表达，分析二者与患者临床病理特征及预后的关系。结果在卵巢癌组织中，OCT-4主要表达在细胞质，CD117主要表达在细胞膜和细胞质；OCT-4阳性表达率为74.3%（52/70），CD117阳性表达率为68.6%（48/70）。OCT-4在低分化、高CA125水平（≥500 U/ml）、无腹腔积液、对化疗药物敏感的卵巢癌组织中阳性率分别为92.1%（35/38）、87.5%（28/32）、88.9%（24/27）、78.7%（48/61），与中高分化、低CA125水平（〈500 U/ml）、有腹腔积液、对化疗药物耐药的卵巢癌组织比较，差异均有统计学意义（P值分别为0.000、0.020、0.047、0.043）。CD117在低分化及有腹腔积液的卵巢癌组织中阳性率分别为84.2%（32/38）、79.1%（34/43），高于中高分化、无腹腔积液的卵巢癌组织，差异均有统计学意义（P值分别为0.006、0.017）。OCT-4阳性表达、有腹腔积液及低分化患者总生存期更短（均P〈0.05）。腹腔积液和分化程度是卵巢癌患者预后的独立影响因素（均P〈0.05）。结论OCT-4可以作为预测卵巢癌患者药物敏感性及预后评估的重要参考指标。ObjectiveTo investigate the relationship between expressions of OCT-4, CD117 and clinicopathological features and prognosis of patients with ovarian cancer.MethodsA total of 70 paraffin-embedded tissues of patients with ovarian cancer from January 2010 to February 2016 in Shanxi Provincial Cancer Hospital were collected. The expressions of OCT-4 and CD117 were detected by immunohistochemistry.ResultsOCT-4 was mainly expressed in cytoplasm, while CD117 was expressed in cell membrane and cytoplasm. The positive expression rate of OCT-4 was 74.3% （52/70）, and the positive expression rate of CD117 was 68.6% （48/70）. The positive expression rates of OCT-4 in ovarian cancer tissues with poorly differentiation and high CA125 levels （≥500 U/ml）, no peritoneal effusion and sensitive to chemotherapy drugs were 92.1% （35/38）, 87.5% （28/32）, 88.9% （24/27）, and 78.7% （48/61）, respectively, which were higher than those in ovarian cancer tissues with well and moderately differentiation, low CA125 levels （〈500 U/ml）, peritoneal effusion and resistance to chemotherapy drugs, the differences were statistically significant （P values were 0.000, 0.020, 0.047, and 0.043）. The positive expression rates of CD117 in ovarian cancer tissues with poorly differentiation and peritoneal effusion were 84.2% （32/38） and 79.1% （34/43）, respectively, which were higher than those in ovarian cancer tissues with well and moderately differentiation and no peritoneal effusion, the differences were statistically significant （P values were 0.006 and 0.017）. Patients with OCT-4-positive expression, peritoneal effusion, and poorly differentiation had a shorter overall survival time （all P 〈 0.05）. The peritoneal effusion and differentiation were independent prognostic factors in patients with ovarian cancer （both P 〈 0.05）.ConclusionOCT-4 can be used as an important reference for predicting drug sensitivity and evaluating prognosis in patients with ovarian cancer.

关 键 词：卵巢肿瘤 OCT-4 CD117 免疫组织化学 预后 

分 类 号：R737.31[医药卫生—肿瘤]